NGNE Neurogene Inc
Price (delayed)
$15.41
Market cap
$230.06M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.28
Enterprise value
$105.57M
neoleukin therapeutics, inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. the company's lead product candidate is nl-201, a de novo protein designed
Highlights
NGNE's quick ratio has soared by 140% YoY and by 134% from the previous quarter
NGNE's equity has soared by 126% QoQ and by 67% YoY
Neurogene's net income has shrunk by 107% YoY and by 41% QoQ
Key stats
What are the main financial stats of NGNE
Market
Valuations
Earnings
Shares outstanding
14.93M
Market cap
$230.06M
Enterprise value
$105.57M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.74
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$83.53M
Net income
-$75.14M
EBIT
-$75.13M
EBITDA
-$71.14M
Free cash flow
-$71.41M
Per share
Balance sheet
Liquidity
EPS
-$4.28
EPS diluted
-$4.28
Free cash flow per share
-$4.07
Book value per share
$20.89
Revenue per share
$0
TBVPS
$19.11
Total assets
$335.73M
Total liabilities
$25.36M
Debt
$12.43M
Equity
$310.38M
Working capital
$300.77M
Debt to equity
0.04
Current ratio
20.84
Quick ratio
20.63
Net debt/EBITDA
1.75
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-34.4%
Return on equity
-38.9%
Return on invested capital
-73.6%
Return on capital employed
-23.4%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NGNE stock price
How has the Neurogene stock price performed over time
Intraday
0.26%
1 week
34.12%
1 month
8.52%
1 year
-48.41%
YTD
-32.59%
QTD
31.6%
Financial performance
How have Neurogene's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$83.53M
Net income
-$75.14M
Gross margin
N/A
Net margin
N/A
Neurogene's net income has shrunk by 107% YoY and by 41% QoQ
NGNE's operating income has dropped by 50% year-on-year and by 9% since the previous quarter
Growth
What is Neurogene's growth rate over time
Valuation
What is Neurogene stock price valuation
P/E
N/A
P/B
0.74
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
NGNE's EPS has soared by 96% YoY and by 87% QoQ
NGNE's equity has soared by 126% QoQ and by 67% YoY
The stock's price to book (P/B) is 75% less than its last 4 quarters average of 3.0 and 61% less than its 5-year quarterly average of 1.9
Efficiency
How efficient is Neurogene business performance
The company's return on invested capital fell by 38% YoY but it rose by 3.8% QoQ
NGNE's return on assets is down by 23% since the previous quarter and by 19% year-on-year
The ROE has contracted by 19% from the previous quarter and by 13% YoY
Dividends
What is NGNE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NGNE.
Financial health
How did Neurogene financials performed over time
NGNE's quick ratio has soared by 140% YoY and by 134% from the previous quarter
Neurogene's current ratio has surged by 139% YoY and by 129% QoQ
NGNE's debt is 96% smaller than its equity
NGNE's equity has soared by 126% QoQ and by 67% YoY
Neurogene's debt to equity has plunged by 60% from the previous quarter and by 50% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.